Genpharmasec Ltd
BSE:531592
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.93
6.97
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Genpharmasec Ltd
Cash & Cash Equivalents
Genpharmasec Ltd
Cash & Cash Equivalents Peer Comparison
MSTCLTD
ADANIENT
REFEX
INDIAMART
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
G
|
Genpharmasec Ltd
BSE:531592
|
Cash & Cash Equivalents
₹29.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
S
|
Shree Global Tradefin Ltd
BSE:512463
|
Cash & Cash Equivalents
₹1.8B
|
CAGR 3-Years
194%
|
CAGR 5-Years
406%
|
CAGR 10-Years
N/A
|
|
|
MSTC Ltd
NSE:MSTCLTD
|
Cash & Cash Equivalents
₹11.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Adani Enterprises Ltd
NSE:ADANIENT
|
Cash & Cash Equivalents
₹70.7B
|
CAGR 3-Years
57%
|
CAGR 5-Years
33%
|
CAGR 10-Years
7%
|
|
|
Refex Industries Ltd
NSE:REFEX
|
Cash & Cash Equivalents
₹482.3m
|
CAGR 3-Years
32%
|
CAGR 5-Years
66%
|
CAGR 10-Years
N/A
|
|
|
Indiamart Intermesh Ltd
NSE:INDIAMART
|
Cash & Cash Equivalents
₹410.2m
|
CAGR 3-Years
35%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
See Also
What is Genpharmasec Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
29.2m
INR
Based on the financial report for Jun 30, 2024, Genpharmasec Ltd's Cash & Cash Equivalents amounts to 29.2m INR.
What is Genpharmasec Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-11%
Over the last year, the Cash & Cash Equivalents growth was 634%. The average annual Cash & Cash Equivalents growth rates for Genpharmasec Ltd have been -6% over the past three years , -11% over the past five years .
You don't have any saved screeners yet
